Objective Low-dose, long-term 
Introduction

Chronic airway mucus hypersecretion is seen in a variety of respiratory diseases including sinobronchial syndrome (SBS) such as diffuse panbronchiolitis (DPB), chronic bronchitis, and bronchiectasis. DPB is a representative disease of airway mucus hypersecretion and had been a fatal disease until low-dose, long-term macrolide therapy was developed (1). DPB is initiated from small airway inflammation, which is persistent with chronic sinobronchial infection. Accompanying airway mucus hypersecretion, progressive airflow obstruction occurs during the natural course of the disease, and subsequently leads to respiratory failure. Low-dose, long-term macrolide therapy has been shown to be an effective treatment and has increased the survival rate of the patients with DPB (1, 2). The mechanism of action of low-dose macrolide therapy primarily demonstrates an anti-inflammatory effect with the suppression of mucus and water secretion in the airway lumen, but is not due to an antibacterial activity (3). The volume of sputum and cough frequency often decreases in many of the patients with DPB by the macrolide therapy.
Bronchiectasis, chronic bronchitis, and sinobronchial syndrome are thought to be similar to DPB regarding the presence of chronic airway infection accompanied by chronic airway mucus hypersecretion. As a result, low-dose macrolide therapy has been shown to be an effective in the treatment of these disorders as it is in DPB (4, 5 
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sensitive for the detected bacteria that are identified in the expectorated sputum. However, none of the participating subjects developed an acute exacerbation during the trial period. Figure 1 shows 
Changes in the VAS scores after treatment with tiotropium
Radiological findings
The radiological findings (Chest X-ray and CT) were compared regarding the findings before and 3 months after the treatment. No improvement in the radiological findings was observed in any patient. There was no change in the thickness of the bronchial wall, or in the number of micronodules in the lung field after the treatment.
Pulmonary function tests
The results of the pulmonary function test are shown in 
low-dose, long-term macrolide therapy is known to often be effective (1, 2, 4, 5). The principal mechanisms of action of this treatment modality for these disorders are thought to be the suppression of airway secretion due to the inhibition of water and mucin secretion
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from epithelial cells (8, 9) and anti-inflammatory effects (10) (11) (12) (13) (14) (15) . In these three cases, cholinergic innervation is known to be the predominant motor control of mucus secretion in the airway (15 T a b l e 2 . Di s e a s e -c l a s s i f i e d An a l y s i s f o r t h e P e r c e n t a g e Ch a n g e s i n t h Airway mucus hypersecretion has been reported to contribute to the mortality (23) (24) (25) and frequent respiratory infection (25, 26) 
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